Multifunctional selenium nanoparticles with Galangin-induced HepG2 cell apoptosis through p38 and AKT signalling pathway | Zendy

Yinghua Li | Zendy; Min Guo | Zendy; Zhengfang Lin | Zendy; Mingqi Zhao | Zendy; Yu Xia | Zendy; Changbing Wang | Zendy; Tiantian Xu | Zendy; Bing Zhu | Zendy

Open Access

Multifunctional selenium nanoparticles with Galangin-induced HepG2 cell apoptosis through p38 and AKT signalling pathway

Author(s) -

Yinghua Li,

Min Guo,

Zhengfang Lin,

Mingqi Zhao,

Yu Xia,

Changbing Wang,

Tiantian Xu,

Bing Zhu

Publication year - 2018

Publication title -

royal society open science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.84

H-Index - 51

ISSN - 2054-5703

DOI - 10.1098/rsos.180509

Subject(s) - apoptosis , phosphatidylserine , galangin , cancer cell , protein kinase b , cancer research , chemistry , cancer , microbiology and biotechnology , biology , biochemistry , antioxidant , membrane , genetics , phospholipid , quercetin , kaempferol

The morbidity and mortality of hepatocellular carcinoma, the most common cancer, are increasing continuously worldwide. Galangin (Ga) has been demonstrated to possess anti-cancer effect, but the efficacy of Ga was limited by its low permeability and poor solubility. To develop aqueous formulation and improve the anti-cancer activity of Ga, surface decoration of functionalized selenium nanoparticles with Ga (Se@Ga) was synthesized in the present study. The aim of this study was to evaluate the anti-cancer effect of Se@Ga and the mechanism on HepG2 cells. Se@Ga-induced HepG2 cell apoptosis was confirmed by depletion of mitochondrial membrane potential, translocation of phosphatidylserine and caspase-3 activation. Furthermore, Se@Ga enhanced the anti-cancer activity of HepG2 cells through ROS-mediated AKT and p38 signalling pathways. In summary, these results suggest that Se@Ga might be potential candidate chemotherapy for cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research